End-Stage Chronic Heart Failure

Among the top stories in cardiology last week were a preview of presentations from the European Society of Cardiology Congress that could affect clinical practice, and a randomized clinical trial presented at the ESC Congress that found evolocumab was well-tolerated and substantially reduced LDL levels when combined with statin therapy.

The FDA has established a pathway to marketing for Revascor, an investigational cell therapy used for the prevention of postimplantation mucosal bleeding in patients with end-stage chronic heart failure who require a left ventricular assist device.